A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized study
Central review of flow cytometry results highlights discordance in MRD assessment, indicating limited prognostic value in acute myeloid leukemia trials.
Key Points
Centrally reviewed MRD outcomes demonstrated significant prognostic value for overall survival, contrasting the limited predictive power of local assessments.
Concordance between local and central MRD evaluations was lower than expected, with Cohen's kappa indicating poor agreement in both MRD assessment stages.
A total of 87.7% of patients achieved measurable residual disease results locally, while only 54.9% were centrally reviewed, raising concerns about interlaboratory variability.
The findings emphasize the necessity for expert central review in multicenter clinical trials to ensure reliable MRD analysis and improve outcomes.